Homologous recombination deficiency and PARP inhibitors in therapeutics

Bull Cancer. 2021 Nov 16:S0007-4551(21)00439-2. doi: 10.1016/j.bulcan.2021.09.015. Online ahead of print.ABSTRACTPARP inhibitors are effective in different types of tumors such as ovarian, breast, prostate and pancreatic cancer. Many studies are in progress and may lead to prescription evolution. PARP inhibitors prescription is almost reserved to patients with a constitutional BRCA mutation or a somatic BRCA alteration or a tumor with a deficiency in homologous recombination. Nowadays, the diagnosis of homologous recombination deficit, HRD, is possible with the prescription of a myChoice CDx (Myriad) test. PARP inhibitors are studied in association with chemotherapy and targeted therapies but also with radiotherapy and with immune checkpoint inhibitors. Access to PARP inhibitors is challenged with the emergence of resistance mechanism. Various trials are now studying the possibility of reversing these resistance mechanisms.PMID:34799081 | DOI:10.1016/j.bulcan.2021.09.015
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

This study offers a reasonable chance of benefit. It would be nice to see if these patients again respond to immunotherapy.” The FDA approved Opdivo and Yervoy, an immunotherapy combination, for first-line treatment of pleural mesothelioma in 2020. It was the first new systemic approval in more than 16 years. However, it only increased the median overall survival time from 14.1 months to 18.1 months, when compared to standard chemotherapy. Find Immunotherapy Clinical Trials Learn how to access mesothelioma clinical trial...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Exp Hematol Oncol. 2021 Dec 29;10(1):59. doi: 10.1186/s40164-021-00251-0.ABSTRACTSelinexor, an oral selective inhibitor of nuclear export (SINE), was demonstrated to hinder the DNA damage repair (DDR) system by reducing DDR proteins while enhancing the killing of cancer cells by DDR-based therapeutics in vivo studies. In this single-center, multi-arm phase 1b study, selinexor with carboplatin, doxorubicin and cyclophosphamide (DC), irinotecan with fluorouracil and folinic acid (FOLFIRI), irinotecan, and capecitabine and oxaliplatin (XELOX), were employed as separate parallel arms. Eligible patients have relapsed/ metastati...
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research
Clin Genet. 2021 Dec 20. doi: 10.1111/cge.14100. Online ahead of print.ABSTRACTPURPOSE: Investigate whether disparities and other factors influence referral to genetic counseling and testing for hereditary breast and ovarian cancer syndrome (HBOC) in a large health care system.METHODS: Examination of clinical, demographic, and socioeconomic factors from electronic health records associated with genetic referral and testing within 12 months after a new cancer diagnosed between 8/1/2013 and 12/31/2018.RESULTS: For patients meeting institutional criteria for HBOC testing, 60.6% were referred for genetic counseling, 88% of who...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
Cancer J. 2021 Nov-Dec 01;27(6):521-528. doi: 10.1097/PPO.0000000000000556.ABSTRACTPoly(ADP-ribose) polymerase (PARP) inhibitors have transformed the therapeutic landscape for advanced ovarian cancer and expanded treatment options for other tumor types, including breast, pancreas, and prostate cancer. Yet, despite the success of PARP inhibitors in our current therapeutic armamentarium, not all patients benefit because of primary resistance, whereas different acquired resistance mechanisms can lead to disease progression on therapy. In addition, the toxicity profile of PARP inhibitors, primarily myelosuppression, has led to...
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Study